Neurotrope 10-Q14 Nov 132013 Q3 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2013	Nov. 13, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'Neurotrope, Inc.	'
Entity Central Index Key	'0001513856	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	21,740,000
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Period Focus	'Q3	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
ASSETS	'	'
Cash	$15,556,074	$0
Prepaid expenses	92,958	0
TOTAL CURRENT ASSETS	15,649,032	0
TOTAL ASSETS	15,649,032	0
LIABILITIES AND SHAREHOLDERSâ€™ DEFICIT	'	'
Accounts payable and accrued expenses - related party	49,878	1,240,636
Accounts payable and accrued expenses	82,305	192,342
Advances from related party	0	4,815
TOTAL CURRENT LIABILITIES	132,183	1,437,793
Commitments and contingencies	'	'
Convertible redeemable preferred stock, Series A, $.0001 par value, 50,000,000 shares authorized; 21,920,000 shares issued and outstanding, liquidation preference of $21,920,000 plus dividends accruable at 8% per annum of $560,782	18,971,572	0
SHAREHOLDERS' DEFICIT	'	'
Common stock - 300,000,000 shares authorized, $.0001 par value; 21,690,400 issued and outstanding at December 31, 2012; 21,740,000 shares issued and outstanding at September 30, 2013	2,174	2,169
Additional paid-in capital	3,779,548	0
Deficit accumulated during the development stage	-7,236,445	-1,439,962
TOTAL SHAREHOLDERS' DEFICIT	-3,454,723	-1,437,793
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$15,649,032	$0

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets [Parenthetical] (USD $)	Sep. 30, 2013	Dec. 31, 2012
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares, Issued	21,740,000	21,690,400
Common Stock, Shares, Outstanding	21,740,000	21,690,400
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Shares Issued	21,920,000	0
Preferred Stock, Shares Outstanding	21,920,000	0
Preferred Stock, Liquidation Preference, Value	$21,920,000	$0
Dividends Payable Percentage	8.00%	0.00%
Dividends Payable	$560,782	$0

Statement_of_Operations

Statement of Operations (USD $)	3 Months Ended	9 Months Ended	11 Months Ended
Statement of Operations (USD $)	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
OPERATING EXPENSES:	'	'	'
Research and development - related party	$137,123	$456,017	$1,439,508
General and administrative - related party	3,454,428	4,114,754	4,371,899
General and administrative	879,387	1,225,712	1,422,869
TOTAL OPERATING EXPENSES	4,470,938	5,796,483	7,234,276
Net loss before income taxes	-4,470,938	-5,796,483	-7,234,276
Provision for income taxes	0	0	0
Net loss	($4,470,938)	($5,796,483)	($7,234,276)
PER SHARE DATA:	'	'	'
Basic and diluted loss per common share (in dollar per share)	($0.21)	($0.27)	($0.33)
Basic and diluted weighted average common shares outstanding (in shares)	21,702,680	21,696,219	21,695,342

Statement_of_Changes_in_Shareh

Statement of Changes in Shareholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]
Balance at Oct. 31, 2012	$0	$269	$0	($269)
Balance (in shares) at Oct. 31, 2012	'	2,690,400	'	'
Issuance of common stock	0	1,900	0	-1,900
Issuance of common stock, (in shares)	'	19,000,000	'	'
Net (loss)	-1,437,793	'	'	-1,437,793
Balance at Dec. 31, 2012	-1,437,793	2,169	0	-1,439,962
Balance (in shares) at Dec. 31, 2012	'	21,690,400	'	'
Issuance of common stock for consulting fees	-44,640	5	44,635	'
Issuance of common stock for consulting fees, (in shares)	'	49,600	'	'
Stock based compensation	2,928,485	'	2,928,485	'
Issuance of common stock warrants	806,428	'	806,428	'
Net (loss)	-5,796,483	0	0	-5,796,483
Balance at Sep. 30, 2013	($3,454,723)	$2,174	$3,779,548	($7,236,445)
Balance (in shares) at Sep. 30, 2013	'	21,740,000	'	'

Statement_of_Cash_Flows

Statement of Cash Flows (USD $)	9 Months Ended	11 Months Ended
Statement of Cash Flows (USD $)	Sep. 30, 2013	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($5,796,483)	($7,234,276)
Adjustments to reconcile net loss to net cash used by operating activities	'	'
Stock based compensation	2,928,485	2,928,485
Consulting services paid by issuance of common stock	44,640	44,640
Changes in assets and liabilities	'	'
Increase in prepaid expenses	-92,958	-92,958
(Decrease) increase in accounts payable and accrued expenses - related party	-1,190,758	49,878
(Decrease) increase in accounts payable and accrued expenses	-110,037	82,305
Net Cash Used by Operating Activities	-4,217,111	-4,221,926
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Issuance of preferred stock	19,778,000	19,778,000
Repayment of advances from related party	-4,815	0
Net Cash Provided by Financing Activities	19,773,185	19,778,000
NET INCREASE IN CASH	15,556,074	15,556,074
CASH AT BEGINNING OF PERIOD	0	0
CASH AT END OF PERIOD	$15,556,074	$15,556,074

Organization_and_Nature_of_Pla

Organization and Nature of Planned Business:	9 Months Ended
Organization and Nature of Planned Business:	Sep. 30, 2013
GENERAL ORGANIZATION AND BUSINESS [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 – Organization and Nature of Planned Business:

	References in these notes to the unaudited condensed consolidated financial statements to “Neurotrope, Inc.,” “we,” “us,” “our Company” refer to Neurotrope, Inc. and its consolidated subsidiary Neurotrope Biosciences, Inc. (“NBI”). NBI was incorporated in Delaware on October 31, 2012. NBI was formed to advance new diagnostic and therapeutic technologies in the field of neurodegenerative disease, primarily Alzheimer’s Disease. NBI plans to collaborate with Blanchette Rockefeller Neurosciences Institute (“BRNI”), a related party, in this process. The exclusive rights to the licensed technology transferred to the Company on February 28, 2013 (see Note 3).

	On August 23, 2013, a wholly owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013 (“Acquisition Sub”) merged (the “Reverse Merger”) with and into NBI. NBI was the surviving corporation in the Reverse Merger and became the Company’s wholly owned subsidiary. All of the outstanding NBI common stock was converted into shares of Neurotrope, Inc. common stock on a one-for-one basis.

	The Merger is being accounted for as a reverse-merger and recapitalization with NBI as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the Merger are those of NBI and are recorded at the historical cost basis of NBI and the consolidated financial statements after completion of the Merger include the assets and liabilities of NBI and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and NBI from the closing date of the Merger. The stockholders’ equity section has been retroactively restated for all periods presented to reflect the accounting effect of the reverse merger transaction on the basis of the 1:1 exchange ratio on the Merger date. All references to “we,” ”our,” or the “Company” in these financial statements refer to operations and capital transactions of NBI for all periods prior to the Merger.

	As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of NBI, and will continue the existing business operations of NBI as a publicly-traded company.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2013
GENERAL ORGANIZATION AND BUSINESS [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	Note 2 – Basis of Presentation

	The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for the interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Results for the three and nine month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.

Contractual_Commitments

Contractual Commitments:	9 Months Ended
Contractual Commitments:	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments Disclosure [Text Block]	'
	Note 3 – Contractual Commitments:

	From January 1, 2013 through February 28, 2013, the Company compensated its President under an independent contractor agreement at the rate of $20,833 per month (see Note 5). On February 25, 2013, the Company executed a four-year employment agreement, effective March 1, 2013, with its President. This agreement provides for an annual salary of $250,000 and annual bonus of $50,000, which shall increase to an annual salary of $300,000 and an annual bonus of $100,000 effective as of the later of (a) February 28, 2015 or (b) the closing by the Company of a Series B Preferred Stock financing as described in Note 5 below.

	Effective February 28, 2013, the Company executed an agreement with Ramat Consulting Corp. (“Ramat”), a related party, for consulting services, including business development and marketing consulting, for a five-year period, subject to annual renewals thereafter. Ramat's annual fee is $50,000, payable in monthly installments of $4,167, plus pre-approved travel and other reimbursable expenses. Ramat is also entitled to an option, with a term of ten years, to purchase 300,000 shares of common stock of the Company at an exercise price of $1.00 per share. The option shall be deemed to have vested with respect to 20% of the shares as of February 28, 2013, and the balance shall vest on a daily basis over the four-year period beginning on February 28, 2013. An entity related to Ramat purchased one million shares of Series A preferred stock on the effective date of this agreement.

	Effective April 15, 2013, the Company executed an agreement with Weisberg Consulting LLC for consulting services, including assistance in locating appropriate business opportunities with corporate partners related to the licensing of the Company's products and/or technologies to these partners and the consummation of agreements to form strategic alliances with these entities. The initial term of this agreement is for three months at a fee of $12,000 per month plus reimbursable expenses and is subject to renewal on a monthly basis at a fee of $14,000 per month. In addition, the agreement provides for a bonus of $25,000 to be paid upon the execution of a transaction. The agreement term ended on July 15, 2013 and has been renewed on a month-to month-basis.

	Effective April 17, 2013, the Company executed an agreement with Dominick & Dominick LLC for consulting services related to the structuring of a potential reverse merger with a publicly-held shell company. The fees under this agreement consist of $25,000 payable upon the execution of a merger term sheet and $50,000 payable upon the commencement of due diligence activities related to the merger. Through September 30, 2013, the Company has recognized $75,000 of expenses relating to this agreement in general and administrative expenses on the statement of operations.

	Effective June 2, 2013, the Company executed a consulting agreement with Medical Cash Management Solutions, LLC for services as the Company's chief financial officer on an independent contractor basis through November 30, 2013 at a fee of $20,000 per month plus reimbursable expenses. This agreement is subject to renewal terms as agreed to by the parties. Effective October 1, 2013, the Company canceled its agreement with Medical Cash Management Solutions, LLC and hired its managing member as the Company chief financial officer (See “Subsequent Events” below).

Summary_of_Significant_Account

Summary of Significant Accounting Policies:	9 Months Ended
Summary of Significant Accounting Policies:	Sep. 30, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 4 - Summary of Significant Accounting Policies:

	Development Stage:

	The Company is considered to be a development stage company, as defined by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915-10, in that the Company is devoting substantially all of its efforts to establishing a new business where planned principal operations have commenced, but no revenues have been derived from these operations.

	In addition, the Company’s licensed technology may not be ready for commercialization for several years, if at all. The Company expects to continue to incur losses at least until commercialization, because it anticipates that its expenditures on research and development and administrative activities will significantly exceed any potential revenues during the period. The Company cannot predict when, if ever, it will become profitable.

	Use of Estimates:

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

	Cash and Cash Equivalents:

	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2013, the Company’s cash balances exceeded the current insured amounts under the Federal Deposit Insurance Corporation.

	Research and Development Costs:

	All research and development costs, including costs to maintain or expand the patent portfolio which do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2013 and December 31, 2012.

	Income Taxes:

	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carry forwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carry forwards, which will either be taxable or deductible when the related assets, liabilities or carry forwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

	Uncertain Tax Positions:

	The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions.

	The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through December 31, 2012.

	In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed.

	Risks and Uncertainties:

	The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks including the potential for business failure.

Related_Party_Transactions

Related Party Transactions:	9 Months Ended
Related Party Transactions:	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 5 – Related Party Transactions:

	The Company incurred consulting fees of $41,667 to its President during the period from January 1, 2013 to February 28, 2013 (see Note 3).

	One director of the Company, until November 8, 2013, is also a director of BRNI. A second director of the Company is both the president and a director of BRNI. Both of these current and former directors are stockholders of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”) that owns 41.5% of the Company's outstanding common stock.

	Effective October 31, 2012, the Company executed a Technology License and Services Agreement with BRNI, a related party, and two entities affiliated with BRNI (the “Agreement”). Under the terms of the Agreement, BRNI provides research services and grants the Company the exclusive and nontransferable license right to certain patent and intellectual property which became effective upon the Company's completion of a Series A Preferred Stock financing generating net proceeds to the Company of at least $8,000,000 on February 28, 2013. The Agreement terminates on the latter of the date (i) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (ii) the last of the intellectual property enters the public domain.

	The research services provided under the Agreement commenced on April 2, 2012. The Agreement requires the Company to reimburse BRNI for services rendered (the “Services Reimbursement”) on a pro-rated, thirty month basis, with respect to the period of time elapsed from April 2, 2012 through the date of the Series A Preferred Stock financing on February 28, 2013. BRNI invoiced the Company $1,198,696 for service reimbursements through December 31, 2012 and an additional $266,666 from January 1, 2013 to February 28, 2013.

	After the initial Series A Preferred Stock financing, the License Agreement requires the Company to enter into scope of work agreements with BRNI, the preferred service provider for any research and development services or other related scientific assistance and support services. The Company shall not engage any other person other than BRNI to perform research or development services or other related scientific assistance without prior written consent of BRNI with such consent not unreasonably withheld. BRNI and Neurotrope may agree to have a third party provide services identical or similar to such services to Neurotrope in the case where BRNI is demonstrably unable to do so or such third party is demonstrably in a superior position to do so.

	In addition to the fees under the services reimbursement and scope of work agreements, the Agreement requires the Company to pay BRNI a “Fixed Research Fee”, commencing the date that the Company completes a Series B Preferred Stock financing resulting in net proceeds of at least $25,000,000 (the “Series B Financing”). The fixed research fee is (i) a pro- rata amount of $1,000,000 in the year the Company completes such financing (ii) $1,000,000 per year for five calendar years subsequent to such financing and (iii) an annual fixed research fee in an amount to be negotiated and agreed upon no later than 90 days prior to the end of the fifth calendar year following the completion of such financing to be paid with respect to each remaining calendar year during the term of the Agreement. The Company had not completed this Series B Financing at September 30, 2013 (see Note 8) and, accordingly, no such fee was due as of that date.

	The Agreement also requires the payment of royalties ranging between 2% and 5% of the Company’s revenues generated from the licensed patents and other intellectual property, dependent upon the percentage ownership that NRVI holds in the Company. Under the Agreement, the Company is required to prepay royalty fees at a rate of 5% of all investor funds raised in the Series A or Series B Preferred Stock financings or any subsequent rounds of financing prior to a public offering, less commissions. On March 25, 2013, the Company prepaid $409,549 in royalties under the Agreement and paid the remainder due of $60,319 in July 2013 relating to the May 7, 2013 Series A preferred stock financing. On August 29, 2013, the Company paid $520,252 in prepaid royalties relating to the August 23, 2013 Series A preferred stock financing. These royalties are expensed in “general and administrative expenses – related party” in the statement of operations.

	On August 21, 2013, the Company and BRNI amended the Technology License and Services Agreement to clarify certain provisions.

	On August 22, 2013, the Board of Directors agreed to compensate its Chairman $9,000 per month for ongoing services to the Company relating to product development and negotiation of agreements with BRNI and outside contractors and consultants.

	Effective August 28, 2013, the Company signed a statement of work (“SOW”) with BRNI pursuant to its licensing agreement (Noted above) whereas the Company has contracted for the further development of its AD diagnostic product. Pursuant to the SOW, the Company is obligated to pay BRNI a total of $1,645,470 in 12 equal monthly installments of $137,123, payable on the first business day of each month. These payments are for operating expenses associated with BRNI’s diagnostic laboratories. Operating expenses that are incurred in excess of this total amount are the responsibility of BRNI unless prior approval is obtained from the Company. The SOW may be extended if BRNI provides the Company with two months advanced notice that the SOW objectives are not met within the initial 12 month period. The Company will agree to continue funding the SOW at the same monthly rate for a period not to exceed an additional six (6) months to conclude the first anticipated clinical trial for the AD diagnostic product. In addition, the Company has agreed to pay an estimated $877,300 in external costs to complete the first clinical trial.

Income_Taxes

Income Taxes:	9 Months Ended
Income Taxes:	Sep. 30, 2013
INCOME TAXES [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 6 – Income Taxes:

	The Company incurred a net operating loss for income tax purposes of $7,234,276 for the period from October 31, 2012 (inception) through September 30, 2013. This amount is available for carry forward for use in offsetting taxable income of future years through 2032. The net operating loss carry forward resulted in a deferred tax asset of $2,170,282 at September 30, 2013, which is reduced to zero by an offsetting valuation allowance. As a result, there is no provision for income taxes.

Common_Stock

Common Stock:	9 Months Ended
Common Stock:	Sep. 30, 2013
STOCKHOLDERS' EQUITY [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
	Note 7 – Common Stock:

	On February 28, 2013, NBI amended and restated its Certificate of Incorporation to authorize 45,000,000 common shares at a par value of $0.01. On that date, the Company issued 19,000,000 common shares. This recapitalization has been presented retroactively in the accompanying financial statements.

	On June 20, 2013, BlueFlash Communications, Inc., a Florida corporation (“BlueFlash”), entered into an Agreement and Plan of Merger (the “Plan of Merger”) with Neurotrope, Inc., its wholly owned Nevada subsidiary, pursuant to which BlueFlash would merge with and into Neurotrope (the “Reincorporation Merger”). The Plan of Merger was amended by the Amendment to Agreement and Plan of Merger between the parties, dated July 10, 2013 (the “Amendment”). The purpose of the Merger was to re-domicile BlueFlash from Florida to Nevada, and to effect a name change and recapitalization as described below.

	On August 5, 2013, Articles of Merger were filed with both the Secretary of State of the State of Nevada and the Secretary of State of the State of Florida, pursuant to which the Reincorporation Merger was effective as of August 9, 2013. Upon effectiveness of the Merger, Neurotrope, Inc.’s Articles of Incorporation and Neurotrope, Inc.’s Amended and Restated Bylaws became the Articles of Incorporation and Amended and Restated Bylaws of the registrant.

	Neurotrope, Inc., has an authorized share capital of 300,000,000 shares of common stock, par value $0.0001 per share (“Neurotrope Common Stock”) and 50,000,000 shares of “blank check” preferred stock, par value $0.0001 per share. Prior to the Reincorporation Merger, Neurotrope, Inc. had 100 shares of its Neurotrope Common Stock outstanding, held by BlueFlash, and therefore was a wholly-owned subsidiary of BlueFlash. Prior to the Merger, Neurotrope, Inc. had no assets, liabilities or business.

	Pursuant to the Plan of Merger, among other things, (i) each share of common stock of BlueFlash, $0.0001 par value per share (“BlueFlash Common Stock”) was automatically converted into 2.242 shares of Neurotrope Common Stock.

	On August 21, 2013, the NBI amended its articles of incorporation to increase its authorized shares of common stock from 45,000,000 shares to 57,000,000 shares.

	On August 23, 2013, the Reverse Merger occurred as described in Note 1 above, and all of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock on a one-for-one basis.

	In connection with the Reverse Merger and pursuant to a Split-Off Agreement, Neurotrope, Inc. transferred its pre-Reverse Merger business to Marissa Watson, its pre-Reverse Merger majority stockholder, in exchange for the surrender by her and cancellation of 20,178,000 shares of Neurotrope, Inc. common stock.

Preferred_Stock

Preferred Stock:	9 Months Ended
Preferred Stock:	Sep. 30, 2013
Equity [Abstract]	'
Preferred Stock [Text Block]	'
	Note 8 – Preferred Stock:

	Through a private placement, NBI issued 9,073,300 preferred shares at $1 per share on that date, resulting in gross proceeds of $9,073,300. In connection with the February 28, 2013 closing of the private placement, the Company was required to pay the placement agent, Allied Beacon Partners, Inc., a cash fee equal to the sum of (a) 10% of the proceeds received from purchasers sourced by Allied Beacon Partners, Inc. and (b) 5% of the proceeds received from purchasers sourced by the Company. No fee was payable on proceeds received from purchasers who were already stockholders of the Company. The total cash fee that the Company was required to pay in connection with this closing was $882,330. The Company was also obligated to issue to Allied Beacon Partners, Inc. warrants for the purchase of common stock and Series A preferred stock of the Company in connection with the closing. The aggregate number of shares subject to such warrants was the sum of (x) 10% of the number of shares purchased by purchasers sourced by Allied Beacon Partners, Inc. and (b) 5% of the number of shares purchased by purchasers sourced by the Company. No warrants were earned on proceeds received from purchasers who were already stockholders of the Company.

	On May 17, 2013, NBI issued an additional 1,313,325 shares of Series A preferred stock at $1 per share, resulting in gross proceeds of $1,313,325, on which NBI was obligated to provide the placement agent with cash and warrant compensation under the same terms as applied with respect to the February 28, 2013 closing.

	The total number of shares subject to warrants that NBI was required to issue in connection with the February and May 2013 closings was 988,663, consisting of 480,320 shares of common stock and 508,343 shares of Series A preferred stock. These warrants have a term of ten years. The strike price for the common stock warrants is $0.01 per share and the strike price for the Series A preferred stock warrants is $1.00 per share.

	On August 23, 2013, NBI closed a private placement of 11,533,375 additional shares of its Series A preferred stock, for a purchase price of $1.00 per share, for aggregate gross proceeds of $11,533,375 (before deducting placement agent fees and expenses of the offering). All of the 21,920,000 outstanding shares of NBI Series A preferred stock were converted into shares of Neurotrope Inc. Series A convertible preferred stock (the “Series A Preferred Stock”) on a one-for-one basis in the Reverse Merger. This additional financing was in conjunction with the Company’s merger with a publicly reporting shell company (See Note 1 above).

	The Company agreed to pay the placement agent in the offering a cash commission of 10% of the gross funds raised from investors in the private placement offering (“PPO”). In addition, the placement agent received (a) for the first $12,000,000 of gross PPO proceeds, (i) warrants exercisable for a period of ten (10) years to purchase a number of shares of Common Stock equal to 7.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 2.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 10% of the number of shares of Series A preferred stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the “Agent Warrants”). As a result of the foregoing, the placement agent was paid an aggregate commission of $1,128,338 and was issued Agent Warrants to purchase 419,680 shares of the Company’s common stock and Agent Warrants to purchase 708,657 shares of the Company’s Series A preferred stock.
	The Series A preferred stock ranks senior with respect to liquidation preference and dividend rights to the common stock and any other class or series of stock that the Company may issue. The Series A preferred stock accrues a dividend at an annual rate of $0.08 per share, when and if declared by the Board of Directors of the Company. No dividends have been declared on the Series A preferred stock. In the event of any voluntary or involuntary liquidation, dissolution or winding-up of our affairs or similar event, a holder of Series A preferred stock will be entitled to be paid, before any distribution or payment may be made to any holders of common stock or other class or series of stock, the liquidation amount (which shall equal $1.00 per share) and the amount of any accrued and unpaid dividends as of such distribution or payment date. Each share of Series A preferred stock is convertible into common stock at the option of the stockholder at a price of $1.00 per share, subject to adjustment. The Series A shares are subject to mandatory conversion upon the vote of holders of a majority of the outstanding shares of Series A preferred stock at any given time, or upon the closing of a sale of common stock to the public at a price of at least $5.00 per share (subject to adjustment in the case of certain events) in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in net proceeds to the Company of at least $30,000,000.The holders of Series A preferred stock are entitled to a class vote on certain Company actions, have the right to elect one of five members of the Company board of directors and have a right of first offer to purchase their pro rata share of equity securities issued by the Company in the future, in addition to certain additional rights and privileges as set forth in the Amended and Restated Certificate of Incorporation and in certain agreements between the Company and the holders thereof.

	On August 21, 2013, NBI increased its authorized shares of preferred stock to 50,000,000 shares. As a result, the Company had a sufficient number of preferred shares to close the August 23, 2013 private placement.

Warrants

Warrants:	9 Months Ended
Warrants:	Sep. 30, 2013
Warrants and Rights Note Disclosure [Abstract]	'
Warrants And Rights Note Disclosure [Text Block]	'
	Note 9 – Warrants:

	During the nine months ended September 30, 2013, in conjunction with the Series A preferred stock financing (see Note 8), the Company issued warrants for 2,117,000 underlying shares, consisting of warrants for 900,000 underlying shares of common stock and warrants for 1,217,000 underlying shares of Series A preferred stock to the placement agents. Both warrants have a term of ten years. The strike price for the common stock warrants is $0.01 per share and the strike price for the Series A preferred stock warrants is $1.00 per share.

	The 988,663 warrants issued during the six months ended June 30, 2013 were valued using the Black-Scholes option pricing model. The following weighted average assumptions were used for warrants issued; risk free interest rates of 2.57%; expected dividend yield of 0%; expected term of 10 years and expected volatility of 106.0%. The weighted average remaining life of the warrants at June 30, 2013 was assumed to be 10 years. The total calculated fair value of the warrants as of June 30, 2013 is $896,921.

	The 1,128,337 warrants issued during the three months ended September 30, 2013 were valued using the Black-Scholes option pricing model. The following weighted average assumptions were used for these warrants; risk free interest rates of 2.82%; expected dividend yield of 0%; expected term of 10 years and expected volatility of 105.3%. The weighted average remaining life of these warrants at September 30, 2013 was assumed to be 10 years. The total calculated fair value of these warrants as of September 30, 2013 is $1,025,666.

	Of the $1,922,587 total fair value of warrants issued during the nine months ended September 30, 2013, $806,428 has decreased Preferred Stock and increased paid-in-capital in the balance sheet.

Stock_Options

Stock Options:	9 Months Ended
Stock Options:	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	Note 10 – Stock Options:

	Before the Reverse Merger, our Board of Directors adopted, and our stockholders approved, our 2013 Equity Incentive Plan (the “2013 Plan”), which provides for the issuance of incentive awards of up to 7,000,000 shares of the Company’s common stock to officers, key employees, consultants and directors. Upon the closing of the Reverse Merger, options to purchase an aggregate of 5,154,404 shares of the Company’s common stock were issued. Of these options: 1. 3,500,000 options were issued to founding stockholders and 54,404 were granted to a consultant, each with a term of ten years, exercisable at $1.75 per common share, 100% of these options vested on date of grant; 2. 1,050,000 options were issued to four directors (or their affiliates) and 250,000 to a consultant with a term of ten years, exercisable at $1.00 per common share, which vest 20% per year for each of five years after the date of grant, and; 3. 300,000 options were granted to a consultant with a term of ten years, exercisable at $1.00 per common share which vested 20% on date of grant and vest 20% per year over the next four years. These options were issued in conversion of options issued by NBI on February 28, 2013.

	A summary of the Company’s stock option activity for the nine months ended September 30, 2013 is as follows:

		Options Outstanding		Weighted-Average Exercise Price
	Outstanding at December 31, 2012	0
	Options granted	5,154,404	$	1.52
	Options canceled	0		0
	Options exercised	0		0
	Outstanding at September 30, 2013	5,154,404	$	1.52
	Options exercisable	3,676,751	$	1.73

	The weighted-average remaining contractual term of options exercisable and outstanding at September 30, 2013 was approximately 9.90.

	The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: Dividend yield 0%; Volatility 105.25%; Risk-free interest rate 2.82%; weighted average grand date fair value of $0.82 for options exercisable at $1.00 per common share and $0.80 for options exercisable at $1.75 per common share.

	The total stock option-based compensation recorded as operating expense was approximately $2.9 million for the three months and nine months ended September 30, 2013 and from inception to September 30, 2013. Approximately $0.1 million of the expense is classified as research and development and the remaining approximately $2.8 million of stock option-based compensation expense was classified as general and administrative expense.

Common_and_Preferred_Stock_Res

Common and Preferred Stock Reserved for Future Issuances:	9 Months Ended
Common and Preferred Stock Reserved for Future Issuances:	Sep. 30, 2013
Class of Stock Disclosures [Abstract]	'
Schedule of Stock by Class [Table Text Block]	'
	Note 11 – Common and Preferred Stock Reserved for Future Issuances:

	Common stock and preferred stock reserved for future issuances consisted of the following at September 30, 2013:

		Common Stock Reserved	Preferred Stock Reserved
	Common stock warrants outstanding	900,000
	Preferred stock warrants outstanding	1,217,000	1,217,000
	Common stock options outstanding	5,154,404	0
	Conversion of Series A preferred stock	23,000,000
	Total	30,271,404	1,217,000

Subsequent_Events

Subsequent Events:	9 Months Ended
Subsequent Events:	Sep. 30, 2013
SUBSEQUENT EVENTS [Abstract]	'
Subsequent Events [Text Block]	'
	Note 12 – Subsequent Events:

	The Company’s management has evaluated the effects of events occurring through November 14, 2013, the date these financial statements were available to be issued.

	On October 1, 2013, the Company executed a four-year employment agreement, effective October 1, 2013, with its Chief Financial Officer. This agreement provides for an annual salary of $240,000 which shall increase to an annual salary of $275,000 beginning January 1, 2015. In addition, the agreement provides for a $35,000 bonus for year ended December 31, 2013, a $50,000 bonus for year ended December 31, 2014 and a targeted bonus of 50% of base salary for all subsequent years. In addition, on October 1, 2013 the Board granted a qualified stock option to the CFO under the Company’s 2013 Equity Incentive Plan to purchase 650,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.00 per share. These options vest 25% per year over four years, with accelerated vesting of 25% upon a termination without cause or for good reason.

	On October 4, 2013, the Company completed its Series A preferred stock offering through a private placement of 1,080,000 shares of its Series A preferred stock, for a purchase price of $1.00 per share, for aggregate gross proceeds of $1,080,000 (before deducting placement agent fees and expenses of the offering). The Company agreed to pay the placement agent in the offering a cash commission of 10% of the gross funds raised from investors in the PPO. In addition, the placement agent received (a) for the first $12,000,000 of gross PPO proceeds, (i) warrants exercisable for a period of ten (10) years to purchase a number of shares of Common Stock equal to 7.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 2.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 10% of the number of shares of Series A preferred stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the “Agent Warrants”). As a result of the foregoing, the placement agent was paid an aggregate commission of $108,000 and was issued Agent Warrants to purchase 108,000 shares of the Company’s Series A preferred stock based upon the continuation of this raise of Series A. preferred stock and that the placement agent had previously received the maximum of 900,000 common stock warrants.

	On October 18, 2013, the Board of Directors of the Company increased the size of our Board of Directors from five to six members and appointed Paul E. Freiman to fill the vacancy so created, to serve until the next annual meeting of shareholders or until his successor is duly elected and qualified. On the same date, the Board granted a non-qualified stock option to Mr. Freiman under the Company’s 2013 Equity Incentive Plan to purchase 250,000 shares of the Company’s common stock, with a term of ten years, exercisable at $1.50 per share, the last sale price for the common stock as quoted on the OTC Markets on the date of grant. The option will vest 20% per year for each of five years after the date of grant (subject to acceleration of vesting upon a change of control of the Company).

	On November 8, 2013, Ralph Bean resigned as a director of the Company.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies: (Policies)	9 Months Ended
Summary of Significant Accounting Policies: (Policies)	Sep. 30, 2013
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]	'
Development Stage Enterprises Policy [Policy Text Block]	'
	Development Stage:

	The Company is considered to be a development stage company, as defined by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915-10, in that the Company is devoting substantially all of its efforts to establishing a new business where planned principal operations have commenced, but no revenues have been derived from these operations.

	In addition, the Company’s licensed technology may not be ready for commercialization for several years, if at all. The Company expects to continue to incur losses at least until commercialization, because it anticipates that its expenditures on research and development and administrative activities will significantly exceed any potential revenues during the period. The Company cannot predict when, if ever, it will become profitable.

Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates:

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents:

	The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At September 30, 2013, the Company’s cash balances exceeded the current insured amounts under the Federal Deposit Insurance Corporation.

Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Costs:

	All research and development costs, including costs to maintain or expand the patent portfolio which do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at September 30, 2013 and December 31, 2012

Income Tax, Policy [Policy Text Block]	'
	Income Taxes:

	Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the bases of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carry forwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carry forwards, which will either be taxable or deductible when the related assets, liabilities or carry forwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized.

Income Tax Uncertainties, Policy [Policy Text Block]	'
	Uncertain Tax Positions:

	The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The standard also provides guidance on de-recognition, classification, interest and penalties, and accounting in interim periods, disclosure and transitions.

	The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions is from October 31, 2012 (inception) through December 31, 2012.

	In the event the Company was to receive an assessment for interest and/or penalties, it will be classified in the financial statements as selling, general and administrative expense when assessed.

Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Risks and Uncertainties:

	The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risks including the potential for business failure.

Stock_Options_Tables

Stock Options: (Tables)	9 Months Ended
Stock Options: (Tables)	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the Company’s stock option activity for the nine months ended September 30, 2013 is as follows:

		Options Outstanding		Weighted-Average Exercise Price
	Outstanding at December 31, 2012	0
	Options granted	5,154,404	$	1.52
	Options canceled	0		0
	Options exercised	0		0
	Outstanding at September 30, 2013	5,154,404	$	1.52
	Options exercisable	3,676,751	$	1.73

Common_and_Preferred_Stock_Res1

Common and Preferred Stock Reserved for Future Issuances: (Tables)	9 Months Ended
	Sep. 30, 2013
Class of Stock Disclosures [Abstract]	'
Schedule of Guarantor Obligations [Table Text Block]	'
	Common stock and preferred stock reserved for future issuances consisted of the following at September 30, 2013:

		Common Stock Reserved	Preferred Stock Reserved
	Common stock warrants outstanding	900,000
	Preferred stock warrants outstanding	1,217,000	1,217,000
	Common stock options outstanding	5,154,404	0
	Conversion of Series A preferred stock	23,000,000
	Total	30,271,404	1,217,000

Contractual_Commitments_Detail

Contractual Commitments: (Details Textual) (USD $)	2 Months Ended	1 Months Ended			9 Months Ended		1 Months Ended
	Feb. 28, 2013	Feb. 25, 2013	Feb. 28, 2013	Apr. 30, 2013	Sep. 30, 2013	Apr. 30, 2013	Jun. 30, 2013
	Feb. 28, 2013	Independent Contractor Agreement [Member]	Ramat [Member]	Weisberg Consulting LLC [Member]	Dominick Dominick LLC [Member]	Dominick Dominick LLC [Member]	Medical Cash Management Solutions, LLC [Member]
General Contractor Costs	$20,833	'	'	'	'	'	'
Annual Salary Providing Under Agreement	'	250,000	'	'	'	'	'
Annual Bonus Providing Under Agreement	'	50,000	'	'	'	'	'
Increasing Decrease In Annual Salary	'	300,000	'	'	'	'	'
Increasing Decrease In Annual bonus	'	100,000	'	'	'	'	'
Technology Services Costs	'	'	50,000	12,000	'	'	20,000
Service Cost Paid Under Installment	'	'	4,167	'	'	'	'
Stock option entitled to related party	'	'	300,000	'	'	'	'
Stock option entitled to related party purchase price per share	'	'	$1	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	'	'	20.00%	'	'	'	'
Consulting fee renewal amount	'	'	'	14,000	'	'	'
Bonus to consulting services agent	'	'	'	25,000	'	'	'
Consulting fee payable upon execution of merger term sheet	'	'	'	'	'	25,000	'
Consulting fee payable upon commencement of due diligence activities related to merger	'	'	'	'	'	50,000	'
Other General and Administrative Expense	'	'	'	'	$75,000	'	'

Related_Party_Transactions_Det

Related Party Transactions: (Details Textual) (USD $)

9 Months Ended

11 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Fixed Research Fee [Member]

Services Reimbursement [Member]

Statement Of Work Agreement [Member]

Series A Preferred Stock [Member]

President [Member]

Director [Member]

Board of Directors Chairman [Member]

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

Monthly Installment [Member]

Fixed Research Fee [Member]

Technology License And Services Agreement [Member]

Minimum [Member]

Professional Fees

$41,667

Equity Method Investment, Ownership Percentage

41.50%

Proceeds from Issuance of Preferred Stock and Preference Stock

19,778,000

25,000,000

8,000,000

Technology Services Costs

1,198,696

Additional Technology Sevices Costs

266,666

Research and Development Expense, Total

1,000,000

Research Fee Subsequent Terms

'5 years

Royalties Percentage

5.00%

2.00%

5.00%

Royalty Expense

409,549

60,319

Royalty Prepaid

520,252

Salaries, Wages and Officers Compensation, Total

9,000

Payments to Acquire Productive Assets, Total

1,645,470

137,123

Development Cost Payment Term

'12 years

Additional Payments To Acquire Productive Assets

$877,300

Income_Taxes_Details_Textual

Income Taxes: (Details Textual) (USD $)	11 Months Ended
Income Taxes: (Details Textual) (USD $)	Sep. 30, 2013
Deferred Tax Assets, Gross, Total	$2,170,282
Operating Income (Loss)	$7,234,276

Common_Stock_Details_Textual

Common Stock: (Details Textual) (USD $)	Sep. 30, 2013	Aug. 23, 2013	Aug. 21, 2013	Aug. 05, 2013	Dec. 31, 2012	Aug. 05, 2013	Feb. 28, 2013	Aug. 31, 2013	Aug. 31, 2013	Aug. 05, 2013
						Blue Flash Common Stock [Member]	NBI [Member]	NBI [Member]	NBI [Member]	Blue Flash [Member]
								Maximum [Member]	Minimum [Member]
Common Stock, Shares Authorized	300,000,000	'	'	300,000,000	300,000,000	'	45,000,000	57,000,000	45,000,000	'
Common Stock, Par or Stated Value Per Share	$0.00	$1	'	$0.00	$0.00	$0.00	$0.01	'	'	'
Common Stock, Shares, Issued	21,740,000	'	'	'	21,690,400	'	19,000,000	'	'	'
Preferred Stock, Shares Authorized	50,000,000	'	50,000,000	50,000,000	50,000,000	'	'	'	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	'	'	$0.00	$0.00	'	'	'	'	'
Common Stock, Shares, Outstanding	21,740,000	'	'	'	21,690,400	'	'	'	'	100
Business Acquisition, Equity Interest Issued or Issuable, Description	'	'	'	'	'	'each share of common stock of BlueFlash, $0.0001 par value per share (BlueFlash Common Stock) was automatically converted into 2.242 shares of Neurotrope Common Stock.	'	'	'	'
Surrender Of Share	'	20,178,000	'	'	'	'	'	'	'	'

Preferred_Stock_Details_Textua

Preferred Stock: (Details Textual) (USD $)

1 Months Ended

9 Months Ended

Aug. 31, 2013

Sep. 30, 2013

Aug. 23, 2013

Aug. 21, 2013

Aug. 05, 2013

31-May-13

Dec. 31, 2012

Sep. 30, 2013

Aug. 23, 2013

31-May-13

Aug. 31, 2013

Feb. 28, 2013

Sep. 30, 2013

Feb. 28, 2013

Aug. 23, 2013

31-May-13

Aug. 23, 2013

17-May-13

Sep. 30, 2013

Common Stock [Member]

Agent Warrants [Member]

NBI [Member]

Private Placement [Member]

Series A Preferred Stock [Member]

NBI [Member]

Private Placement [Member]

Preferred Stock, Shares Issued

21,920,000

9,073,300

11,533,375

1,313,325

Preferred Stock, Par or Stated Value Per Share

$0.00

Preferred Stock, Value, Issued

$9,073,300

$11,533,375

$1,313,325

Payment To Private Placement Agent Description

'a cash fee equal to the sum of (a) 10% of the proceeds received from purchasers sourced by Allied Beacon Partners, Inc. and (b) 5% of the proceeds received from purchasers sourced by the Company

Fees and Commissions

882,330

108,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

988,663

480,320

508,343

900,000

Percentage of cash commission agreed to pay placement agent

10.00%

Proceeds from Issuance of Warrants

12,000,000

Warrants issued to placement agent description

'for the first $12,000,000 of gross PPO proceeds, (i) warrants exercisable for a period of ten (10) years to purchase a number of shares of Common Stock equal to 7.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 2.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 10% of the number of shares of Series A preferred stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the Agent Warrants). As a result of the foregoing, the placement agent was paid an aggregate commission of $1,128,338 and was issued Agent Warrants to purchase 419,680 shares of the Companys common stock and Agent Warrants to purchase 708,657 shares of the Companys Series A preferred stock

Fees and Commissions, Transfer Agent

1,128,338

Warrants to be purchased by agent

419,680

708,657

Preferred Stock, Dividend Rate, Per-Dollar-Amount

$0.08

Common Stock, Par or Stated Value Per Share

$0.00

$0.01

Sale of Stock, Price Per Share

Conversion of Stock, Amount Issued

$30,000,000

Preferred Stock, Shares Authorized

50,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.01

Warrants_Details_Textual

Warrants: (Details Textual) (USD $)	9 Months Ended				3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 30, 2013	Aug. 23, 2013	Aug. 05, 2013	Dec. 31, 2012	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
	Sep. 30, 2013	Aug. 23, 2013	Aug. 05, 2013	Dec. 31, 2012	Warrants Not Settleable in Cash [Member]	Warrants Not Settleable in Cash [Member]	Common Stock [Member]	Series A Preferred Stock [Member]
Warrant Issued	2,117,000	'	'	'	1,128,337	988,663	900,000	1,217,000
Fair Value Of Warrant	'	'	'	'	'	896,921	'	'
Common Stock, Par or Stated Value Per Share	$0.00	$1	$0.00	$0.00	'	'	$0.01	'
Preferred Stock, Par or Stated Value Per Share	$0.00	'	$0.00	$0.00	'	'	'	'
Fair Value Assumptions, Risk Free Interest Rate	'	'	'	'	2.82%	2.57%	'	'
Fair Value Assumptions, Expected Dividend Rate	'	'	'	'	0.00%	0.00%	'	'
Fair Value Assumptions, Expected Term	'	'	'	'	'10 years	'10 years	'	'
Fair Value Assumptions, Expected Volatility Rate	'	'	'	'	105.30%	106.00%	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	'	'	'	'	'10 years	'10 years	'	'
Fair Value Of Warrant Total	$1,922,587	'	'	'	'	'	'	'
Preferred Stock Value Decreased	806,428	'	'	'	'	'	'	'
Common Stock Value Incresed	$806,428	'	'	'	'	'	'	'

Stock_Options_Details

Stock Options: (Details) (USD $)	9 Months Ended
Stock Options: (Details) (USD $)	Sep. 30, 2013
Outstanding at December 31, 2012	0
Options granted	5,154,404
Options canceled	0
Options exercised	0
Outstanding at September 30, 2013	5,154,404
Options exercisable	3,676,751
Weighted-Average Exercise Price, Outstanding at December 31, 2012	'
Weighted-Average Exercise Price, Options granted	$1.52
Weighted-Average Exercise Price, Options canceled	$0
Weighted-Average Exercise Price, Options exercised	$0
Weighted-Average Exercise Price, Outstanding at September 30, 2013	$1.52
Weighted-Average Exercise Price, Options exercisable	$1.73
Qualifed Stock Option [Member] \| Subsequent Event [Member] \| Employment Contracts [Member]	'
Weighted-Average Exercise Price, Options exercisable	$1

Stock_Options_Details_Textual

Stock Options: (Details Textual) (USD $)

9 Months Ended

11 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Option Two [Member]

Employee Stock Option [Member]

Option one [Member]

Equity Incentive Plan 2013 [Member]

Founding Stock Holder [Member]

Consultant One [Member]

Founding Stock Holder and Consultant One [Member]

Consultant Two [Member]

Director And Consultant Two [Member]

Consultant Three [Member]

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

7,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

5,154,404

3,500,000

54,404

250,000

300,000

1,050,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'0 years

'10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price

$1.73

$1.75

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage

100.00%

20.00%

Number of Director

Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period

'5 years

'4 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

105.25%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

2.82%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$0.80

$0.82

Share Price

$1.75

Share-based Compensation, Total

$2,928,485

$2,900,000

Research and Development Expense, Total

100,000

Allocated Share-based Compensation Expense

$2,800,000

Common_and_Preferred_Stock_Res2

Common and Preferred Stock Reserved for Future Issuances: (Details)	Sep. 30, 2013
Common Stock Reserved	30,271,404
Preferred Stock Reserved	1,217,000
Common Stock Warrant Outstanding [Member]	'
Common Stock Reserved	900,000
Preferred Stock Warrant Outstanding [Member]	'
Common Stock Reserved	1,217,000
Preferred Stock Reserved	1,217,000
Common Stock Option Outstanding [Member]	'
Common Stock Reserved	5,154,404
Preferred Stock Reserved	0
Series A Preferred Stock [Member]	'
Common Stock Reserved	23,000,000

Subsequent_Events_Details_Text

Subsequent Events: (Details Textual) (USD $)	Aug. 23, 2013	31-May-13	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	31-May-13	Sep. 30, 2013
			Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
			Non-Qualified Stock Option [Member]	Employment Contracts [Member]	Employment Contracts [Member]	Employment Contracts [Member]	Employment Contracts [Member]			Private Placement [Member]
					Qualifed Stock Option [Member]	Minimum [Member]	Maximum [Member]
Sale of Stock, Price Per Share	$5	'	'	'	'	'	'	'	'	$1
Proceeds from Issuance of Private Placement	'	'	'	'	'	'	'	$12,000,000	'	$1,080,000
Stock Issued During Period, Shares, New Issues	'	'	'	'	'	'	'	'	'	1,080,000
Bonus	'	'	'	'	'	35,000	50,000	'	'	'
Targeted Bonus Percentage Of Base Salary	'	'	'	50.00%	'	'	'	'	'	'
Officers Compensation	'	'	'	'	'	240,000	275,000	'	'	'
Additional Technology Services Costs	'	'	20.00%	'	25.00%	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	'	'	250,000	'	650,000	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Options Vested Period	'	'	'5 years	'	'4 years	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	'	'	'10 years	'	'10 years	'	'	'	'	'
Sale of Stock, Number of Shares Issued in Transaction	'	'	'	'	'	'	'	'	'	1,080,000
Percentage Of Private Placement Agent Cash Commission	'	'	'	'	'	'	'	'	'	10.00%
Fees and Commissions	'	'	'	'	'	'	'	'	'	$108,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	988,663	'	'	'	'	'	'	508,343	900,000
Sale of Stock, Nature of Operations	'	'	'	'	'	'	'	'	'	'(i) warrants exercisable for a period of ten (10) years to purchase a number of shares of Common Stock equal to 7.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $0.01, and (ii) warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 2.5% of the number of shares of Series A preferred stock sold to investors introduced by it, with a per share exercise price of $1.00; and (b) on gross PPO proceeds in excess of $12,000,000, warrants exercisable for a period of ten (10) years to purchase a number of shares of Series A preferred stock equal to 10% of the number of shares of Series A preferred stock sold to investors introduced by it, with an exercise price of $1.00 per share (collectively, the Agent Warrants). As a result of the foregoing, the placement agent was paid an aggregate commission of $108,000 and was issued Agent Warrants to purchase 108,000 shares of the Companys Series A preferred stock based upon the continuation of this raise of Series A. preferred stock and that the placement agent had previously received the maximum of 900,000 common stock warrants.